Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
startups
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
alzheimer's disease
antibiotics
axial spondyloarthritis
bausch health
biogen
biology
boston blog main
boston top stories
boston university
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cancer immunotherapy
car-t immunotherapy
cell therapy
clinical trials
cluster headache
crispr
deals
detroit blog main
detroit top stories
diagnostics
digital health
dihydroergotamine
dimitry nuyten
drug prices
eddingpharm
eli lilly
elizabeth holmes
endeavor
fremanezumab
What
biopharmaceutical
2
×
new
approval
bio
biogen’s
called
celgene
cells
celularity
companies
company
convo
creating
derived
diamandis
drug
earlier
endeavor
failures
focus
founder
gene
global
hold
human
key
littered
medicine
million
myriad
nash
news
peter
placenta
placentas
potentials
price
prize
regenerative
remains
Language
Current search:
biopharmaceutical
×
biotech
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@techcrunch.com
6 years ago
With $250 million, Peter Diamandis’ new startup is all about taking stem cells from placentas